Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue specialty drug Coverage & Prior Auth …
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    Newly Marketed and Self‑Administered Specialty Drugs — Coverage List and Prior Authorization Requirements

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists newly marketed prescription and specialty medications with prior authorization (PA), quantity limits (QL), and limited distribution drug (LDD) designations; informs providers and pharmacies about coverage requirements and dispensing channels for Florida Blue members.

    Policy Summary
    PayerFlorida Blue
    PolicyNewly Marketed and Self‑Administered Specialty Drugs — Coverage List and Prior Authorization Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization per the member's plan before dispensing drugs listed with 'PA'.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    20+pages/chunks of drug listings included in this part
    Multipledrugs requiring PA
    Multipledrugs marked LDD
    3pages with NOT COVERED listings
    LDD, PA, QLcoverage designations explained

    Coverage Determinations and Listings

    Newly Marketed Drugs Review

    Coverage determination and listing rules

    Newly marketed drug review: Newly marketed prescription medications may not be covered until the Pharmacy Therapeutics Committee reviews the medication to determine if it will be covered and, if covered, which tier applies based on safety, efficacy, and availability of other class products.

    Providers should check the 'New to Market Drug' list for current status and formulary tiering.

    Plan-specific Coverage and PA

    Coverage requires plan-specific checks

    Plan and PA program verification: Refer to the member contract benefit and the Prior Authorization Program Information and Forms guide to determine whether the medication is included in the PA program and whether it is covered by the member's plan.

    Prior Authorization requirements may vary by plan; certain specialty drugs may not be covered by certain plans. Member cost share may be higher for self-administered specialty drugs not obtained at in-network specialty pharmacies (Accredo or CVS/Caremark Specialty Pharmacy).

    Limited distribution and preferred pharmacy: If a drug is designated as a Limited Distribution Drug (LDD), dispense only through the specified specialty dispensing pharmacy; CVS/Caremark is the preferred in‑network pharmacy for hemophilia products.

    Use the Limited Distribution Drugs list to identify the appropriate dispensing pharmacy.

    Provider support: If coverage or PA inclusion is unclear after consulting plan materials and the PA guide, contact the Provider Contact Center or member Customer Service for assistance.

    Provider Contact Center: 1-800-727-2227; Customer Service number is on the back of the member's ID card.

    Some specialty medications listed in this document may not be covered for all members. Refer to the member contract benefit and the Prior Authorization Program Information and Forms guide to confirm whether a specific drug is included in the member's plan and PA program. Coverage rules, including PA requirements and available dispensing channels, can vary by plan; providers should verify plan-specific coverage before dispensing.

    Drugs that appear in the “Self‑Administered Specialty Drugs that are NOT Covered*” lists and are explicitly labeled NOT COVERED are excluded from payment and will be denied if submitted for coverage. Examples appear throughout the NOT COVERED lists (e.g., Abrilada, Amjevita, Gleevec, Tecfidera, Xyrem, Zytiga and many others); providers should not submit claims for medications shown as NOT COVERED for the member’s plan.

    Provider Requirements and Impact

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required for Listed Drugs — Many drugs in the lists are designated as requiring Prior Authorization (PA). Providers must obtain PA per the member's plan before dispensing. Coverage may be denied if PA is not obtained.

    • PA designations are shown next to drug names (PA).
    • Some drugs are Limited Distribution Drugs (LDD) — dispensing pharmacy information available via the Limited Distribution Drugs link.
    • Quantity Limits (QL) also apply to many listed drugs.
    Prior Authorization

    Prior Authorization Required for Specialty Drugs

    Prior authorization is required for many listed specialty drugs prior to coverage. Providers should confirm PA requirements for the specific member plan and for specialty products that may be excluded from some plans.

    • Specialty drugs marked with PA must have authorization prior to claim submission.
    • Some drugs are covered as self-administered or provider-administered specialty pharmacy drugs as noted in footnotes.

    Document Purpose and Scope

    This section functions as an index-style listing of newly marketed and specialty medications that may require Prior Authorization (PA), be designated as Limited Distribution Drugs (LDD), or have Quantity Limits (QL). It identifies drugs with coverage designations (LDD, PA, QL), indicates preferred in-network specialty pharmacies for certain products, and directs providers to check the member contract and PA program guides or contact the Provider Contact Center for plan‑specific requirements.

    Key Terms and Designations

    LDD / PA / QL — Definitions
    LDDLimited Distribution Drug — product is only available from specific specialty pharmacies; the appropriate dispensing pharmacy can be found on the Limited Distribution Drugs list.
    PAPrior Authorization — prior approval required per the member's plan before the medication will be covered.
    QLQuantity Limit — coverage is subject to a specified quantity threshold where QL is indicated.
    Coverage designations and links
    LDD — Limited Distribution DrugDesignated drugs are limited to specific dispensing pharmacies; 'The appropriate dispensing pharmacy can be found here: Limited Distribution Drugs.'
    PA — Prior AuthorizationMany listed drugs require prior authorization; providers must obtain PA per the member contract and Prior Authorization Program Information and Forms guide.

    Step Therapy Requirements

    StepRequirementNotes
    1Step therapy may be required per planRefer to the member contract benefit and the Prior Authorization Program Information and Forms guide for specific step edits; requirements vary by plan and by drug.

    Quantity Limit Notes

    Multiple listed drugs — Quantity limits
    ApplicabilityQuantity limits apply to drugs listed with the QL designation.
    Multiple drugs affectedNumerous listed products across the A–Z tables are marked with QL; check the specific drug line for the limit indicator.
    Provider actionWhen QL is indicated, dispense and billing must conform to the documented quantity limit for the member's plan.

    Specialty Pharmacy and Dispensing

    Billing Rule

    Use Preferred In‑Network Specialty Pharmacies When Required

    Certain specialty drugs are preferred to be obtained from in‑network specialty pharmacies (Accredo or CVS/Caremark Specialty Pharmacy); obtain member drugs per site-of-care preferences to avoid higher member cost share.

    • CVSICaremark is the preferred in-network pharmacy for hemophilia products.
    • Member cost share may be higher for self-administered specialty drugs not obtained at in-network specialty pharmacies.
    Policy Summary
    PayerFlorida Blue
    PolicyNewly Marketed and Self‑Administered Specialty Drugs — Coverage List and Prior Authorization Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization per the member's plan before dispensing drugs listed with 'PA'.
    SourceLink
    On This Page
    Coverage Determinations and ListingsProvider Requirements and ImpactDocument Purpose and ScopeKey Terms and DesignationsStep Therapy RequirementsQuantity Limit NotesSpecialty Pharmacy and Dispensing
  1. CVS Caremark is the preferred in‑network pharmacy for hemophilia products for applicable items.
  2. Step Therapy

    Step Therapy Advisory

    Step therapy requirements may vary by plan and are not fully specified in these lists. Providers should consult the member contract and the Prior Authorization Program Information and Forms guide for any step-therapy or step-edit requirements that apply.

    • Step edits, if applicable, will be enforced per the member's benefit plan.
    • Refer to plan-specific PA guides for details on required trials or alternatives.
    Documentation Required

    Provider Documentation and Contact

    Provider documentation and contact — Providers must refer to the member contract benefit and the Prior Authorization Program Information and Forms guide to determine PA program inclusion and coverage details. If questions remain after consulting the table and guides, contact the Provider Contact Center.

    • Provider Contact Center: 1-800-727-2227 (health care providers and office staff only)
    • Customer Service phone number is on the back of the member's insurance card
    • Use the Limited Distribution Drugs resource to identify the appropriate dispensing pharmacy for LDD products.
    Denial Risk

    Prior Authorization and Plan Exclusions

    Prior authorization and plan exclusions — Coverage may be denied if a medication is subject to PA and PA is not obtained. Certain specialty drugs may not be covered by certain plans; providers should verify coverage before prescribing or dispensing.

    • Medications labeled NOT COVERED in the lists will be denied if submitted for coverage.
    • Some products are not covered for certain plan types; consult the member's contract for exclusions.
    • Even when PA is obtained, noncoverage designations (NOT COVERED) override PA approval.
    Denial Risk

    Not Covered Drugs — Denial Risk

    Not covered drugs — denial risk — Drugs explicitly listed as NOT COVERED are not eligible for payment and will be denied if submitted for coverage. Providers should identify alternate, covered therapies and confirm benefit specifics with the member's plan before dispensing.

    • Multiple self-administered specialty drugs in the lists are labeled NOT COVERED — these will be denied.
    • NOT COVERED status applies regardless of PA status; do not submit claims for payment for these products.
    QL — Quantity LimitWhere QL is indicated, quantity limits apply to the drug as listed on the table.
    Footnote clarifications
    Self- vs Provider‑Administered (Footnote 1)Footnote 1: Some products are covered either as Self‑Administered or Provider‑Administered Specialty Pharmacy drugs — refer to the listing for the footnote designation.
    CVSICaremark preferred for hemophilia (Footnote 2)Footnote 2: CVSICaremark is the preferred in‑network pharmacy for hemophilia products.
    NOT COVERED listings and footnoteEntries labeled 'NOT COVERED' (e.g., in the Self‑Administered Specialty Drugs that are NOT Covered* list) are explicitly not eligible for payment and will be denied if submitted.